SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, has signed a preliminary agreement to produce the candidate Covid-19 vaccine being developed by US drugmaker Johnson & Johnson (J&J) at its Port Elizabeth site, it announced on Monday.

The news was cheered by shareholders, who boosted Aspen’s share price by up to 11.5% in intraday trading, its biggest daily gain since April 18. Its share price closed at R117.65, its highest since October 1...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now